20 results about "Cells progenitors" patented technology

This disclosure relates to cell therapy approaches for treating progranulin (PGRN) deficiencies with human induced pluripotent stem cell (hiPSC)-derived cells. Advantageously, the hiPSC-derived cells (e.g., microglia progenitor cells) described herein can cross-correct PGRN deficiencies in damaged or diseased cells while reducing the amount of endogenous cell ablation that is needed, as demonstrated by experimental results showing restoration of PGRN levels in GRN mutant cells and brain organoids.

The present invention relates to a method for treating aging, and in particular immunosenescence, restoring thymic function and regenerating the thymus in a subject in need thereof, comprising the administration of T cell progenitors comprising CD7+CD34- cells.

Combination therapies comprising oxytocin and gonadotropin releasing hormone are provided. The combinations can be used to treat aging-related neurological diseases or disorders. In addition, downstream effectors of OXT-GnRH combination, including hypothalamic stem / progenitor cells-derived EVs and vesicles containing or loaded with PTMS, can be used to treat aging-related neurological diseases or disorders.

Tissue-specific progenitor cells representing the endoderm, ectoderm, and mesoderm lineages are generated from pluripotent sources. Progenitor cell generation is accomplished by contacting pluripotent stem cells with tissue-specific exosomes, microRNAs, proteins, and peptides, obtained by stressing the tissue under in vitro conditions. In vitro-generated tissue organoids are used as a source of "differentiation factors" for generating individualized progenitor cells. For example, to generate lung progenitor cells, allogeneic stem cells are implanted into decellularized cadaveric lung tissue to form lung structures, which are then exposed to various cellular stressors and conditioned media to differentiate the pluripotent stem cells into progenitor cells. Extracellular matrix can be obtained from decellularized structures seeded with regenerating cells and used to generate organoids, which are then subjected to stress to produce differentiation factors.

The present disclosure is in the field of culturing a homocellular cell culture of progenitor cells form a heterocellular tissue sample. The present disclosure relates to a method for specifically generating muscle progenitor cells or adipogenic progenitor cells from an isolated tissue sample, preferably a muscle tissue sample, e.g., from mammalian origin, preferably from bovine, ovine, murine, or porcine origin. The method includes culturing a heterocellular tissue sample comprising a muscle progenitor cell and an adipogenic progenitor cell in a selection medium including comprsing at least one compound which specifically promotes the proliferation of muscle progenitor cells or of adipogenic progenitor cells leading to a homocellular cell culture. Further, the present disclosure relates to the selection medium which facilitates selective generation of muscle progenitor cells or of adipogenic progenitor cells. The method and selection medium of the invention can be used for producing homocellular cell cultures of muscle progenitor cells or of adipogenic progenitor cells. The homocellular cell cultures produced according to the present disclosure can be used to produce a cell culture-based meat product, preferably for animal or human consumption.

The present disclosure concerns a microglia progenitor cell derived from bone marrow and / or placental stromal cells and / or umbilical cord stromal cell and methods for their isolation; as well as use of said cells for therapy of disorders of the CNS.

This disclosure relates to CRISPR-related systems and components for targeting, editing, and / or regulating the expression of the FLI-1 (Friend virus leukemia integration 1 transcription factor, Fli-1 proto-oncogene, ETS transcription factor) gene. This disclosure also relates to methods and applications relating to genetically modified cells, including T cells or T cell progenitor cells.

Methods and systems for improving or enabling delivery of antibodies, immunoglobulin receptors, or immunotherapy agents across the Blood-Brain Barrier (BBB) are disclosed. Exosomes are derived from stem cells, immune cell progenitors, or immune cells, and are loaded with an antibody, immunoglobulin receptor, or antibody fragment. Focused energy, preferably low-intensity focused ultrasound, is applied to a region of the BBB of a patient, and loaded exosomes are administered to the patient. Exosomes target the region for delivery of the loaded antibody, receptor, or fragment, either by traversing the BBB at the region or releasing the loaded antibody to neural tissue at the region.

This disclosure relates to CRISPR-related systems and components for targeting, editing, and / or regulating CD70 (differentiation cluster 70) gene expression. This disclosure also relates to methods and applications relating to genetically modified cells, including T cells or T cell progenitor cells.

Methods and systems for improving or enabling delivery of antibodies, immunoglobulin receptors, or immunotherapy agents across the Blood-Brain Barrier (BBB) are disclosed. Exosomes are derived from stem cells, immune cell progenitors, or immune cells, and are loaded with an antibody, immunoglobulin receptor, or antibody fragment. Focused energy, preferably low-intensity focused ultrasound, is applied to a region of the BBB of a patient, and loaded exosomes are administered to the patient. Exosomes target the region for delivery of the loaded antibody, receptor, or fragment, either by traversing the BBB at the region or releasing the loaded antibody to neural tissue at the region.

The present invention relates to a method of treating aging and in particular immune aging, restoring thymus function, and regenerating thymus in a subject in need thereof, the method comprising administering a T cell progenitor cell comprising CD7 + CD34-cells.

The present invention relates to a biological sample bank comprising at least two cell biological sample banks wherein the cells of the cell biological sample bank may be immune cells or hematopoietic stem and progenitor cells (HSPC) or in vitro produced T cell progenitor cells wherein the cells of each cell bank have a specific homozygous human leukocyte antigen (HLA) haplotype. The invention also relates to a method for selecting at least one cell bank, and to the use of the selected cell bank as an agent, in particular for the treatment of immunodeficiencies, immune disorders and / or diseases, lymphopenia or cancer, and covering a large number of patients.

The present invention provides a method for producing human immortalized megakaryocytes and / or human immortalized megakaryocyte progenitor cells and / or human megakaryocyte cell lines (102) from adult CD34 + HSPC (100) capable of maturation into functional megakaryocytes (103) producing functional platelets (104), said method comprising at least the steps of: producing functional platelets (104) by transduction, in particular lentiviral (LV) transduction; an expression cassette comprising at least one gene is introduced into the CD34 + HSPC (100) to effectuate forced expression of the at least one gene wherein the transduced CD34 + HSPC (100) is configured to express at least one gene from the HOXL subclass of the ANTP homologous cassette family and / or the TALE homologous cassette family upon activator-induced expression, and constitutively expressing at least one anti-apoptotic gene from the BCL2 family wherein the transduced CD34 + HSPC (100) is immortalized by expression of the at least one gene from the ANTP homologous cassette family and / or the HOXL subclass of the TALE homologous cassette family, preferably wherein the at least one gene from the HOXL subclass comprises a combination of one of the HOXB8, HOXA7, HOXA10 or HOXB4 genes and at least one of the MEIS1, MEIS2, MEIS3, PBX1, PBX2, PBX3 and / or PBX4 genes, and the at least one anti-apoptosis gene from the BCL2 family comprises BCL2L1 or BCL2L2. The invention further provides a method of producing functional platelets by using the immortalized megakaryocytes and / or immortalized megakaryocyte progenitor cells and / or immortalized megakaryocyte cell lines obtained by the above method. Further, the present invention provides a pharmaceutical composition comprising functional platelets obtained by the above method and its therapeutic use.

The present disclosure is directed to methods of producing oligodendrocyte progenitor cells (OPCs). In addition, methods of treating demyelinating diseases using oligodendrocyte progenitor cells (OPCs) are also disclosed.

The present disclosure provides myeloid cells, microglial progenitor cells, and microglia-like cells in which a mutant gene has been repaired or replaced, and methods of using such cells to treat disease. Mutations in CSF1R were corrected in human induced pluripotent stem cells. The resulting cells were differentiated into microglial progenitors and then transplanted into the brain of xenotransplantation-compatible CSF1R-AFIRE / AFIRE mice, thereby preventing or reversing phenotypes associated with leukodystrophy, including thalamic microbleeds, calcification, astrogliosis, axonal spheroids, synaptic loss, and accumulation of Tau phosphorylated at threonine residue 217.

Methods for generating pre-oligodendrocyte precursor cells (pre-OPCs) and oligodendrocyte progenitor cells (OPCs) from human pluripotent stem cells are provided using chemically defined culture media that allow for the generation of pre-OPCs and OPCs in as few as three days. Culture media, isolated cell populations, and kits are also provided.

In various aspects, the invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. In certain aspects, the invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture media and methods disclosed herein. The pluripotent stem cell-derived definitive HE cells produced by methods provided herein are capable of differentiating into hematopoietic lineage cells comprising T cell progenitors and T cells, in addition to NK cell progenitors, NK cells, NKT cells, or B cells.

The present disclosure, in various aspects and embodiments, provides methods for generating hematopoietic lineages for cell therapy, including erythroid progenitor cells, progenitor erythroblasts, granulocyte-macrophage progenitor cells (GMPs), and megakaryocyte erythroid progenitor cells (MEPs), and erythroid cells. In various embodiments, the invention provides for efficient ex vivo processes for developing such hematopoietic lineages, including but not limited to progenitor erythroblast cells and erythroblast cell lineages, from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and / or more closely resemble the corresponding lineage isolated from peripheral blood or bone marrow. The present invention also provides isolated cells and cell compositions produced by the methods disclosed herein, as well as methods for cell therapy.

Disclosed are: a method for producing a cell population comprising T precursor cells, the method comprising a step (1) for culturing a cell population containing CD34 + cells in the presence of an aromatic hydrocarbon receptor antagonist and an LSD1 degradation inducer; a population of cells comprising T precursor cells obtained by such a method; a drug containing the cell population comprising T precursor cells; and a T cell progenitor cell inducer comprising an aromatic hydrocarbon receptor antagonist and an LSD1 degradation inducer.